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Summary Human head and neck tumours were succesfully transplanted in athymic nude mice. In 14
xenograft lines the effect of 1 to 3 clinically active agents could be tested. Maximum tolerated doses were
given daily for 3-7 days. Growth delay was estimated in terms of the number of volume doubling times
gained by the treatment. Cis-platinum and bleomycin appeared to be effective agents. In all 6 lines in which
cis-platinum was examined, growth delay sometimes followed by complete regression was achieved. In 6/7 lines
a response to bleomycin was observed. There was wide variation in sensitivity to cis-platinum and bleomycin
among the different lines. Methotrexate, effective in 40-60% of patients with head and neck cancer,
essentially showed no activity. Methotrexate produced a minimal growth delay in 1/11 lines treated. Two of
the patients from whom xenografts were obtained responded to methotrexate treatment. The observed lack of
activity of methotrexate against these tumour xenografts indicates that this model has limitations in the
screening of new anticancer agents.
The nude mouse xenograft model seems promising
for the evaluation of anticancer drugs. Xenografted
human tumours generally respond to agents that
are active in the clinic (Povlsen & Jacobsen, 1975,
Kopper & Steel, 1975, Osieka et al., 1977,
Shorthouse et al., 1982). For a few tumours it could
be demonstrated that xenografts reproduced the
patterns of chemotherapeutic response of their
source tumours (Giovanella et al., 1978, Nowak et
al., 1978, Fujita et al., 1980). Furthermore,
Shorthouse et al. (1980) demonstrated in 16
bronchial carcinomas established in immune-
suppressed mice that the response of the xenografts
and their donor tumours were similar. Single agent
chemotherapy is still commonly administered to
patients with head and neck cancer, since no
superior efficacy of a combination treatment has
been proven (DeConti & Schoenfeld, 1981).
Therefore head and neck cancer xenografts are well
suited for a comparison of the response of
xenografted tumours, with that of head and neck
tumours generally in clinical practice and their
source tumour in particular. An evaluation of the
sensitivity of head and neck cancer xenografts to
three drugs that are widely used in the clinic is
described. Two individual comparisons of patient
and xenograft responses to the same agent are
reported.
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Materials and methods
Animals and tumours
Female nude mice (B10.LP/Cpb, 8-10 weeks old)
were obtained from the Centraal Proefdierenbedrijf
TNO (Zeist, the Netherlands). The mice were
maintained under SPF conditions. Cages, bedding,
food and acidified water were autoclaved before
use. Only head and neck tumours from previously
untreated patients were selected for implantation.
Tumour material was dissected in slices measuring
3 x 3 x 1 mm and implanted s.c. in the lateral
thoracic region on both sides of the animal.
Tumours growing in nude mice were serially
transplanted in a similar way. Tumour growth was
measured biweekly using vernier calipers. Tumour
volume was calculated as length x width x
height x 0.5 (Looney et al., 1973). Twelve lines
were established in this laboratory, of which 8 were
reported recently in detail (Braakhuis et al., 1983).
Two lines (HNX-J and -V) were described by
Lindenberger (1981). Lactate dehydrogenase
(LDH) isoenzyme analysis of the xenografts
showed that >80% of the LDH in the tumour was
of human origin (Pesce et al., 1977).
Chemotherapy
To date 14 xenograft lines were found to be
suitable for chemotherapy (see Table I). The
patients from whom lines HNX-TI and HNX-W
were derived received single agent chemotherapy
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(methotrexate) following biopsy of the tumour for
implantation.
Sensitivity was tested in early passages (2-9).
Chemotherapy studies could not be done in each
passage because of a varying pattern of tumour
take. The intention was to include 8 tumours both
in a control and a treated group. Experiments with
<5 tumours in a group were excluded.
Chemotherapy was started when the tumours
reached 100 mm3 (range 50-150mm3). The tumours
were randomly divided into treatment and control
groups. Since the growth rate varied between
individual tumours, treatment was usually started
on different days. The duration of treatment was
limited to a maximum of 10 days. The intention
was to study drug effects in terms of growth delay
rather than cures. The agent was given daily till a
maximum tolerated dose was reached, i.e. the
maximum weight loss of the mice was 15%. For
methotrexate 2 other schedules were used with
injections every 4 and 7 days. Using these two
schedules of methotrexate LD10 doses were studied.
For the treatment and control groups the mean
values of time needed for tumours to grow 2 and 4
times their initial volume were calculated. The
mean values of the control and treated groups were
compared with a one-way analysis of variance,
followed by the Student-Newman-Keuls-test (Sokal
& Rohlf, 1969). Before these tests could be
employed the data were checked for
homoscedasticity and normality. Growth delay was
defined, according to Kopper & Steel (1975) as the
difference between the mean values of the time
needed by the treated and control tumours to grow
from 100 to 200mm3, divided by the mean value of
the time needed by the control tumours to grow
from 100 to 200mm3. In the same way the growth
delay for tumour size increase from 100 to
400mm3. (i.e. for 2 doubling times) was
determined. Growth delay is thus expressed in
terms of the number of volume doubling times
gained by the treatment. This method of analysis
makes it possible to compare lines that have
different rates of growth.
Drugs
Cis-dichlorodiamino-platinum (CDDP, platinol,
Bristol Meyers) was dissolved in distilled water
immediately before i.p. injection. Bleomycin
(BLEO, Lundbeck) was dissolved in distilled water
and stored frozen. Injections were given s.c. in the
back of the animal. Methotrexate (MTX,
Ledertrexate, Lederle) was dissolved in distilled
water and kept at 4°C for a maximum of 14 days.
Injections were given i.p.
Results
Three clinically active drugs were tested on 14 head
and neck cancer xenograft lines, established in
athymic nude mice. Three lines only could be tested
with all 3 drugs. The other lines could not be tested
Table I Characteristics of xenograft lines.
Nomenclature Histology* Site
HNX-B moderately diff. oropharynx
HNX-G well diff. skin
HNX-J moderately diff. lymph node, larynx
HNX-KB well diff. lymph node, unknown
HNX-KE poorly diff. larynx
HNX-KR poorly diff. oral cavity
HNX-LA well diff. lymph node, oral cavity
HNX-LP moderately diff. oral cavity
HNX-P well diff. oral cavity
HNX-PV (mucoepidermoid
ca.) oral cavity
HNX-SG moderately diff. hypopharynx
HNX-TI well diff. oral cavity
HNX-V poorly diff. larynx
HNX-W moderately diff. oral cavity
*All tumours are squamous cell carcinomas except HNX-
PV. Histology and site of origin in the patients from whom
the xenografts were derived. For the sake of clarity, the initial
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Figure 1 Reaction of head and neck cancer xenografts to CDDP and BLEO. Growth delay is expressed in
terms of the mean number of volume doubling times gained by the treatment. Difference between treated and
control group from 100 to 200 and 400mm3 0: significant (P<0.05), A: not significant (P>0.05) and *:
completely regressed tumours in the treated group, no significance tested. CDDP: 3mgkg-' daily for 3-5
days. BLEO: 15mgkg-1 daily for 4-7 days. The numbers of completely regressed tumours divided by the
numbers of treated tumours are shown in the upper panels.
with all drugs: some lines were lost, while others
are still in early passage. The maximum tolerated
dose of CDDP caused a growth delay in all 6 lines
treated (Figure 1.) The growth delay for tumour
doubling varied from 1.4 in one line to a complete
regression of all tumours in another line. BLEO,
using a maximum tolerated dose, showed a
significant growth delay in 6/7 lines (Figure 1). In
3/6 sensitive lines (HNX-G, -SG and -J) the
regrowth of tumours was relatively late; for tumour
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growth from 100-400mm3 a relatively long growth
delay was seen.
MTX was tested using a schedule of 5mgkg-1
for 5-7 days till a maximum tolerated dose was
reached. Only with one line (HNX-PV) was a small,
but significant effect seen (Figure 2). With intention
to mimic the situation in the clinic two high dose
schedules were applied: (i) injection on Days 1 and
8 and (ii) injections on Days 1, 5 and 9. Toxicity
studies with non tumour-bearing animals were
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Figure 2 Reaction of head and neck cancer xenografts to MTX. I. Daily injections of 5mgkg-1 for 5-7 days
II. Injections on Days 1, 5 and 9. Mice with line W tumours received 50 and line B and line TI, 150mgkg-1
per injection. III. Injections on Days 1 and 8, 250mgkg-1 per injection, except lines KR and B which
received 100 and 150mgkg 1 respectively.
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performed to determine the LD10 dose. It was
found that the number of deaths did not correlate
with the dose. Sometimes a high dose was less toxic
than a lower dose. For instance, 100mgkg-1 MTX
on Days 1 and 8 appeared to be more toxic than
250mgkg-1. Because of this variability it was
decided to give relatively high doses (Figure 2).
Another reason for the choice of these high doses
was that the parallel toxicity study with a daily
dose for 5 consecutive days showed that tumour-
bearing animals appear to be less sensitive to MTX
toxicity than non tumour-bearing animals (Table
II). Using the schedule with injections on Day 1
and 8 no difference in toxicity could be found
between tumour-and non tumour-bearing animals.
With these high dose schedules MTX did not
cause a growth delay in any xenograft line (Figure
2). The effects of MTX on the tumours in two
patients from whom xenografts were derived were
known (Table III). Tumours of patients
Table II Toxicity of methotrexate in nude mice with and without
tumour.
No. deathsl
Dose/injection Injections total mice
(mgkg1) on Day (%)
Tumour bearing 250 1,8 4/251 (16)
5 1-5 8/352 (23)
Non tumour-bearing 250 1,8 1/7 (14)
5 1-5 5/7 (71)
Groups of mice were injected i.p. The duration of the experiment
was 40 days.
'Xenografts from 5 different lines.
2Xenografts from 6 different lines.
Table III Reactions to MTX of two head and neck tumours and their
xenografts.
Growth Treatment
delay patientfrom
Xenograft xenograft whom xenograft Reaction
line Schedule (100-200mm3) was derived patient
HNX-TI 5mgkg-1 2 courses of MTX
Day 1-5 0.3 24h infusion 90% tumour
i.a. followed by regression
150mgkg-1 leucovorin-rescue.
Days 1, 5 and 9 0.2 An interval of a week
250mgkg-1
Days 1 and 8 0.3
HNX-W 5mgkg-1 4 courses of MTX
Day 1-5 0.3 24h infusion 50% tumour
i.a. followed by regression
50mgkg-1 leucovorin-rescue.
Days 1, 5 and 9 -0.2 An interval of a week
250mgkg-1
Days 1 and 8 0.3
Xenografts were obtained from the patients prior to chemotherapy.
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corresponding to lines HNX-TI and HNX-W
regressed by 90% and 50% respectively after intra-
arterial MTX treatment.
Discussion
Xenografts of head and neck cancer can be grown
succesfully in athymic nude mice and used for
chemotherapy studies. This study shows that, using
schedules with daily injections, CDDP was an
effective agent; in all 6 xenograft lines a significant
growth delay was found. BLEO was also effective;
in only 1/7 lines was the growth delay insignificant.
Clinical experiences with these agents have shown,
that BLEO and CDDP produce a partial or
complete remission in 38 and 26% of patients,
respectively. (Taylor, 1979). The reason for the
superiority of BLEO and CDDP against the
xenografted tumours in comparison with the
clinical data might be that in nude mice higher drug
levels are attained. Another possibility is that only
xenografts from sensitive patient tumours were
tested since BLEO- and CDDP-insensitive head and
neck cancer xenograft lines have been reported
(Azar et al., 1982). Although all but one of the
tumour lines were sensitive to CDDP and BLEO a
variation in growth delay was evident. For instance,
CDDP caused complete regression of all tumours in
one line and only a minimal growth delay in
another. A better agreement with clinical findings
could be obtained if those lines with a significant
growth delay of less than two doubling times were
considered insensitive in this model.
It is interesting to note that MTX gave only a
minimal response. Tested against 11 lines, only in
one was minimal growth delay observed. Also bolus
injections, which simulated the clinical situation did
not result in growth delay. Partial or complete
remission have been reported for MTX in 40%
(Carter, 1977) to 60% (Kirkwood et al., 1981) of
treated patients. It is therefore unlikely that only
MTX-resistant tumours were implanted into the
nude mice. Alternatively, more succesful xenograft
take could have been characteristic of MTX-
resistant tumours. The mechanisms responsible for
this resistance are perhaps important for an
increased tumorgenicity in nude mice.
It is interesting that for two tumours the reaction
of the xenografts to MTX did not correlate with
the source tumours which were sensitive in the
patient. This experience is contrary to all reported
comparisons, showing similar responses of the
xenografts and the source tumours to the same
treatment (Giovanella et al., 1978, Nowak et al.,
1978, Fujita et al., 1980, Shorthouse et al., 1980).
This observed lack of correlation in the response to
MTX might be attributed to a difference in
pharmacokinetics of MTX between man and
mouse. At least the route of administration is
different. The duration of exposure of xenografts to
MTX may be too short. Experiments with more
frequent drug administration will be carried out to
test this possibility.
Resistance mechanisms potentially induced by
xenografting may also account for the
ineffectiveness of MTX in this model. The
intracellular content of dihydrofolate reductase, the
target enzyme to which MTX binds reversibly, may
be increased or the rate of MTX uptake into the
tumour cell may be decreased (Chabner, 1980).
Another possibility is a reversal of MTX toxicity by
exogenous purine and pyrimidine metabolites,
released by a population of dying tumour cells.
This cell loss could be higher in the xenografts than
in the patient's tumour; a substantial part of the
xenograft is often necrotic. This rescue mechanism
can also be the basis of the protection against
MTX toxicity by the presence of a tumour, as has
been shown in the toxicity studies. With the low
daily doses nucleic acid metabolites can play a role
in protection against MTX toxicity since tumour
(L1210)-bearing mice do not need purines to reverse
MTX toxicity (Straw et al., 1977). Further studies
are needed to elucidate the cause of MTX
ineffectiveness.
Toxicity studies of MTX reveal that the results
are difficult to interpret. Toxicity appeared to be
dependent on the presence of a tumour and,
moreover, an LD10 could not be determined
because of large variability. The policy to give a
daily dose for as long as the mice can tolerate it is
an elegant solution in screening models to
overcome the toxicity problem and is also
economical in mice.
In conclusion, it is clear that response to CDDP
and BLEO varies for the xenograft lines, as has
been shown by other authors using other tumours
and drugs (Bailey et al., 1980, Houghton &
Houghton, 1980 and Nowak et al. 1978). The lack
of correlation between the xenograft and patient
response to MTX appears to indicate that this
model has certain limitations as a screening model
for anticancer agents. It has yet to be established
whether pharmacokinetic differences between man
and mouse or resistance mechanisms in the
xenograft itself are responsible for the lack of effect
of MTX. It is also necessary that more direct
comparisons between xenograft and patient
response with the same agent are made.
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